Advancing management of hypertension through pharmacogenomics

References

• Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, . Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents [see comments] [published erratum appears in N Engl J Med. 1994;330:1689]. N Engl J Med. 1993;328:914–21.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of hypertension—United States, 1999–2002 and 2005–2008. MMWR Morb Mortal Wkly Rep. 2011;60:103–8.
   PubMedGoogle Scholar
• Ma J, Stafford RS. Screening, treatment, and control of hypertension in US private physician offices, 2003–2004. Hypertension. 2008;51:1275–81.
   PubMed Web of Science ®Google Scholar
• Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M, . Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res. 2006;29:143–51.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Roca GC, Pallares-Carratala V, Alonso-Moreno FJ, Escobar-Cervantes C, Barrios V, Llisterri JL, . Blood pressure control and physicians’ therapeutic behavior in a very elderly Spanish hypertensive population. Hypertens Res. 2009;32:753–8.
   PubMed Web of Science ®Google Scholar
• Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, Bohm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens. 2010;24:336–44.
   PubMed Web of Science ®Google Scholar
• Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, . Plasma renin activity predicts blood pressure responses to [beta]-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens. 2010;23:1014–22.
   PubMedGoogle Scholar
• Konoshita T; Investigators tGDOCS. Do genetic variants of the renin-angiotensin system predict blood pressure response to renin-angiotensin system–blocking drugs? A systematic review of pharmacogenomics in the renin-angiotensin system. Curr Hypertens Rep. 2011;13:356–61.
   PubMedGoogle Scholar
• Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, . Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103–9.
   PubMed Web of Science ®Google Scholar
• Fox ER, Young JH, Li Y, Dreisbach AW, Keating BJ, Musani SK, . Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study. Hum Mol Genet. 2011;20:2273–84.
   PubMed Web of Science ®Google Scholar
• Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, . Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet. 2011;43:531–8.
   PubMed Web of Science ®Google Scholar
• Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, . Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009;41:677–87.
   PubMed Web of Science ®Google Scholar
• Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, . Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009;41:666–76.
   PubMed Web of Science ®Google Scholar
• Wain LV, Verwoert GC, O'Reilly PF, Shi G, Johnson T, Johnson AD, . Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet. 2011;43:1005–11.
   PubMed Web of Science ®Google Scholar
• Johnson AD, Newton-Cheh C, Chasman DI, Ehret GB, Johnson T, Rose L, . Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals. Hypertension. 2011;57:903–10.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Liggett SB. Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin Pharmacol Ther. 2011;89:366–78.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther. 2003;74:44–52.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu ZQ, Yu BN, Xu FH, Mo W, Zhou G, . beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther. 2006;80:23–32.
   PubMed Web of Science ®Google Scholar
• Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy. 2007;27:874–87.
   PubMed Web of Science ®Google Scholar
• Filigheddu F, Reid JE, Troffa C, PinnaParpaglia P, Argiolas G, Testa A, . Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade. Pharmacogenomics J. 2004; 4:154–60.
   PubMed Web of Science ®Google Scholar
• Suonsyrja T, Donner K, Hannila-Handelberg T, Fodstad H, Kontula K, Hiltunen TP. Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment. Pharmacogenet Genomics. 2010;20:342–5.
   PubMed Web of Science ®Google Scholar
• Pacanowski MA, Gong Y, Cooper-Dehoff RM, Schork NJ, Shriver MD, Langaee TY, . beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther. 2008;84:715–21.
   PubMed Web of Science ®Google Scholar
• Lemaitre RN, Heckbert SR, Sotoodehnia N, Bis JC, Smith NL, Marciante KD, . [beta]1- and [beta]2-Adrenergic receptor gene variation, [beta]-blocker use and risk of myocardial infarction and stroke. Am J Hypertens. 2008; 21:290–6.
   PubMedGoogle Scholar
• Niu Y, Gong Y, Langaee TY, Davis HM, Elewa H, Beitelshees AL, . Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). Circ Cardiovasc Genet. 2010;3:548–55.
   PubMed Web of Science ®Google Scholar
• Shi PP, Cao XR, Sweezer EM, Kinney TS, Williams NR, Husted RF, . Salt-sensitive hypertension and cardiac hypertrophy in mice deficient in the ubiquitin ligase Nedd4 - 2. Am J Physiol Renal Physiol. 2008;295: F462–70.
   PubMed Web of Science ®Google Scholar
• Dahlberg J, Nilsson LO, von Wowern F, Melander O. Polymorphism in NEDD4L is associated with increased salt sensitivity, reduced levels of P-renin and increased levels of Nt-proANP. PLoS One. 2007;2:e432.
   PubMedGoogle Scholar
• Luo F, Wang Y, Wang X, Sun K, Zhou X, Hui R. A functional variant of NEDD4L is associated with hypertension, antihypertensive response, and orthostatic hypotension. Hypertension. 2009;54:796–801.
   PubMed Web of Science ®Google Scholar
• Russo CJ, Melista E, Cui J, DeStefano AL, Bakris GL, Manolis AJ, . Association of NEDD4L ubiquitin ligase with essential hypertension. Hypertension. 2005;46: 488–91.
   PubMed Web of Science ®Google Scholar
• Zheng X, Morrison AC, Feingold E, Turner ST, Ferrell RE. Association between NEDD4L gene and sodium lithium countertransport. Am J Hypertens. 2011;24:145–8.
   PubMedGoogle Scholar
• Svensson-Farbom P, Wahlstrand B, Almgren P, Dahlberg J, Fava C, Kjeldsen S, . A functional variant of the NEDD4L gene is associated with beneficial treatment response with beta-blockers and diuretics in hypertensive patients. J Hypertens. 2011;29:388–95.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, Cooper-Dehoff RM, . Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J. 2009;157:442–9.
   PubMed Web of Science ®Google Scholar
• Ishigami T, Araki N, Umemura S. Human Nedd4L rs4149601 G allele generates evolutionary new isoform I with C2 domain. Hypertension. 2010;55:e10; author reply e1.
   Google Scholar
• Turner ST, Bailey KR, Fridley BL, Chapman AB, Schwartz GL, Chai HS, . Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension. 2008;52:359–65.
   PubMed Web of Science ®Google Scholar
• Hiltunen TP, Suonsyrja T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Strandberg T, . Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am J Hypertens. 2007;20:311–8.
   PubMed Web of Science ®Google Scholar
• The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Press. 1993;2:312–21.
   PubMedGoogle Scholar
• Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, . Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366: 895–906.
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, . A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–16.
   PubMed Web of Science ®Google Scholar
• Sherva R, Ford CE, Eckfeldt JH, Davis BR, Boerwinkle E, Arnett DK. Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment. Stroke. 2011;42:330–5.
   PubMedGoogle Scholar
• Brugts JJ, Isaacs A, Boersma E, van Duijn CM, Uitterlinden AG, Remme W, . Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. Eur Heart J. 2010;31:1854–64.
   PubMedGoogle Scholar